Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Receivables (2016 - 2025)

Historic Receivables for Arrowhead Pharmaceuticals (ARWR) over the last 14 years, with Q4 2025 value amounting to $228.7 million.

  • Arrowhead Pharmaceuticals' Receivables rose 904792.0% to $228.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $228.7 million, marking a year-over-year increase of 904792.0%. This contributed to the annual value of $6.8 million for FY2025, which is N/A changed from last year.
  • According to the latest figures from Q4 2025, Arrowhead Pharmaceuticals' Receivables is $228.7 million, which was up 904792.0% from $6.8 million recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Receivables ranged from a high of $228.7 million in Q4 2025 and a low of $239000.0 during Q2 2022
  • Its 5-year average for Receivables is $28.0 million, with a median of $3.0 million in 2023.
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Receivables tumbled by 9854.67% in 2021 and then soared by 2572720.0% in 2022.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Receivables stood at $250000.0 in 2021, then soared by 25727.2% to $64.6 million in 2022, then plummeted by 95.29% to $3.0 million in 2023, then fell by 17.74% to $2.5 million in 2024, then surged by 9047.92% to $228.7 million in 2025.
  • Its last three reported values are $228.7 million in Q4 2025, $6.8 million for Q3 2025, and $9.7 million during Q2 2025.